

## ASX Announcement

### Release of Securities from Voluntary Escrow

**6 November 2023** – Race Oncology Limited (“Race”) advises in accordance with ASX Listing Rule 3.10A, that 2,307,925 fully paid ordinary shares in the capital of the Company will be released from voluntary escrow on 14 November 2023.

### About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and a lack of cardiotoxicity.

Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML) exploring anticancer plus cardioprotection in synergy with known standards of care.

As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m<sup>6</sup>A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.

Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at [www.raceoncology.com](http://www.raceoncology.com)

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au).*

**Release authorised by:**

The Race Oncology Board of Directors  
[info@raceoncology.com](mailto:info@raceoncology.com)

**Media contact:**

Jane Lowe +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)